Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Sarah Elitzur, Ruth Shiloh, Jan L. C. Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Thomas Lehrnbecher, Sarah K. Tasian, Oussama Abla, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Nicole Bodmer, Triantafyllia Brozou, Francesco Ceppi, Liliia Chugaeva, Luciano Dalla Pozza, Stephane Ducassou, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Stefanie Junk, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Nizar Mahlaoui, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Marion Strullu, Thai Hoa Tran, Marek Ussowicz, Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, A. Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Veronique Minard-Colin, Kjeld Schmiegelow, Ronit Nirel, Andishe Attarbaschi, Arndt Borkhardt

Blood (2024) 144 (11): 1193–1205.

https://doi.org/10.1182/blood.2024024283

Published: 2024

Includes: Supplemental data

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Sarah Elitzur, Ruth Shiloh, Jan Loeffen, Agata Pastorczak, Masatoshi Takagi, Simon Bomken, Andre Baruchel, Stephane Ducassou, Nizar Mahlaoui, Marion Strullu, Thomas Lehrnbecher, Kjeld Schmiegelow, Oussama Abla, Liliia Anderzhanova, Nira Arad-Cohen, Itziar Astigarraga, Miriam Ben-Harosh, Francesco Ceppi, Nicole Bodmer, Triantafyllia Brozou, Luciano Dalla-Pozza, Gabriele Escherich, Roula Farah, Amber Gibson, Henrik Hasle, Julieta Hoveyan, Elad Jacoby, Janez Jazbec, Alexandra Kolenova, Jelena Lazic, Luca Lo Nigro, Lane Miller, Vassilios Papadakis, Lucie Pecheux, Marta Pillon, Ifat Sarouk, Jan Stary, Eftichia Stiakaki, Sarah K. Tasian, Thai Hoa Tran, Marek Ussowicz, Jose Jaime Verdu-Amoros, Anna Wakulinska, Joanna Zawitkowska, Dominique Stoppa-Lyonnet, Malcolm Taylor, Yosef Shiloh, Shai Izraeli, Ronit Nirel, Veronique Minard-Colin, Andishe Attarbaschi, Arndt Borkhardt

Blood (2023) 142 (Supplement 1): 520.

https://doi.org/10.1182/blood-2023-179333

Published: 2023

Journal Articles

Long-Term Hematopoietic Dysfunction in Patients with Single Large-Scale Mitochondrial DNA Deletion Syndromes

Noa Greenberg-Kushnir, Assaf Arie Barg, Ginette Schiby, Corine Mardoukh, Nira Varda-Bloom, Diana Bar, Yair Anikster, Bella Bielorai, Amos Toren, Elad Jacoby

Blood (2023) 142 (Supplement 1): 4105.

https://doi.org/10.1182/blood-2023-182562

Published: 2023

Journal Articles

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

Inbal Sdayoor, Roni Shouval, Shalev Fried, Ronit Marcus, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Orit Itzhaki, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Michael J Segel, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2023-180115

Published: 2023

Journal Articles

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Shalev Fried, Ivetta Danylesko, Ronit Marcus, Orit Itzhaki, Ronit Yerushalmi, Noga Shem-Tov, Inbal Sdayoor, Roni Shouval, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 6875.

https://doi.org/10.1182/blood-2023-178477

Published: 2023

Journal Articles

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Sara K. Silbert, Cynthia Harrison, D. Nathan Biery, Alexandra Semchenkova, Elena Zerkalenkova, Anna Alonso-Saladrigues, Kaylyn Utley, Ibrahim Aldoss, Liping Zhao, Sneha Fernandes, Jeremy D. Rubinstein, Naomi Torres Carapia, Bill H. Chang, Anant Vatsayan, Barbara De Moerloose, Holly L. Pacenta, Dennis John Kuo, Gabriele Escherich, Benjamin J. Lee, Michele S. Redell, Mandi R. Fitzjohn, Daniel P. Larson, Nicolas Duployez, Raymund S. Cuevo, Rui Rochelle He, David Dickens, Firas El Chaer, Kelly Reed, Matthias Wolfl, Sunil S. Raikar, Süreyya Savaşan, Latika Puri, Zhubin J. Gahvari, Aimee C. Talleur, Hisham Abdel-Azim, Aghiad Chamdin, Marlie R.M. Provost, Vanessa A. Fabrizio, Kerstin Mezger, Alexandra McLean Stevens, Emily M. Hsieh, Hao-Wei Wang, Constance M. Yuan, Ulrich A. Duffner, Jing Pan, Sara Ghorashian, Susana Rives, Chloe Hoang, Kara L. Davis, Elad Jacoby, Alexander Popov, Adam Lamble, Nirali N. Shah

Blood (2023) 142 (Supplement 1): 4202.

https://doi.org/10.1182/blood-2023-182293

Published: 2023

Journal Articles

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 648–650.

https://doi.org/10.1182/blood-2022-162286

Published: 2022

Journal Articles

Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Valeria Ceolin, Erica Brivio, Susan R. Rheingold, Allison Barz Leahy, Britta Julia Vormoor, Maureen M. O'Brien, Jeremy Rubinstein, Krzysztof Kalwak, Barbara De Moerloose, Elad Jacoby, Peter Bader, José L. Fuster, Franco Locatelli, Peter Hoogerbrugge, Friso Calkoen, Christian M. Zwaan

Blood (2021) 138 (Supplement 1): 3824.

https://doi.org/10.1182/blood-2021-146556

Published: 2021

Journal Articles

Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients

Shalev Fried, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Roni Shouval, Joshua A Fein, Zachary Cohen, Elad Jacoby, Michal Besser, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

Blood (2021) 138 (Supplement 1): 910.

https://doi.org/10.1182/blood-2021-147148

Published: 2021

Journal Articles

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Elad Jacoby, MD, Sara Ghorashian, FRCPath, PhD, Britta Julia Vormoor, MD, Barbara De Moerloose, MD, Nicole Bodmer, Michael Maschan, MD, Asaf David Yanir, MD, Bella Bielorai, MD, Srdan Rogosic, Olga Molostova, MD, Claudia Rossig, Amos Toren, MD PhD, Arend von Stackelberg, MD, Jean-Pierre Bourquin, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141940

Published: 2020

Journal Articles

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142314

Published: 2020

Journal Articles

Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies

Katia Beider, Michal J Besser, PhD, Jacob Schachter, MD, Ania Hava Grushchenko-Polaq, Valeria Voevoda, Idit Wolf, Olga Ostrovsky, PhD, Elad Jacoby, MD, Avichai Shimoni, MD, Arnon Nagler, MD MSc

Blood (2019) 134 (Supplement_1): 3234.

https://doi.org/10.1182/blood-2019-128068

Published: 2019

Journal Articles

First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome

Elad Jacoby, MD, Moriya Blumkin, PhD, Yair Anikster, MD PhD, Nira Varda-Bloom, PhD, Julia Pansheen, Omer Bar Yoseph, MD PhD, Noah Gruber, MD, Einat Lahav, MD, Michal J Besser, PhD, Jacob Schachter, MD, Noa Sher, PhD, Natalie Yivgi Ohana, PhD, Amos Toren, MD PhD

Blood (2018) 132 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2018-99-113773

Published: 2018

Journal Articles

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD

Elad Jacoby, Yinmeng Yang, Haiying Qin, Christopher D. Chien, James N. Kochenderfer, Terry J. Fry

Blood (2016) 127 (10): 1361–1370.

https://doi.org/10.1182/blood-2015-08-664250

Published: 2016

Includes: Supplemental data

Journal Articles

CRLF2 /Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells

Christopher Daniel Chien, PhD, Sang Minh Nguyen, BS, Haiying Qin, MS, Elad Jacoby, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 1432.

https://doi.org/10.1182/blood.V126.23.1432.1432

Published: 2015

Journal Articles

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Yinmeng Yang, BS, Tasha Lin, MD, Elad Jacoby, MD, Haiying Qin, MS, Elizabeth Grier Gardner, MD, Christopher Daniel Chien, PhD, Daniel W. Lee, III, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 100.

https://doi.org/10.1182/blood.V126.23.100.100

Published: 2015

Journal Articles

Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR

Elad Jacoby, MD, Sang Minh Nguyen, BS, Kathryn M Welp, Haiying Qin, MS, Yinmeng Yang, BS, Christopher Daniel Chien, PhD, John Shern, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 2524.

https://doi.org/10.1182/blood.V126.23.2524.2524

Published: 2015

Journal Articles

CD19 CAR T Cells Maintain Efficacy in the Allogeneic Environment but Mediate Acute Graft-Versus-Host-Disease Only in the Presence CD19+ Acute Lymphoblastic Leukemia

Elad Jacoby, MD, Haiying Qin, MS, Yinmeng Yang, BS, Christopher Daniel Chien, PhD, Terry J Fry, MD

Blood (2014) 124 (21): 1115.

https://doi.org/10.1182/blood.V124.21.1115.1115

Published: 2014

Journal Articles

41BBL-Based Activation and Expansion of Autologous Natural Killer Cells Results in Enhanced Activity Against Leukemia Including ALL

Ekta Kapadia, MD, Elad Jacoby, MD, Mark Kohler, MDPhD, Waleed Haso, M.S., Christopher Daniel Chien, PhD, Terry J Fry, MD

Blood (2014) 124 (21): 2293.

https://doi.org/10.1182/blood.V124.21.2293.2293

Published: 2014

NARROW

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

ATM Germline Pathogenic Variants Affect Treatment Outcomes in Children with Acute Lymphoblastic Leukemia/Lymphoma and Ataxia Telangiectasia

Long-Term Hematopoietic Dysfunction in Patients with Single Large-Scale Mitochondrial DNA Deletion Syndromes

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies

First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome

Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD

CRLF2 /Tslpr Overexpressing Acute Lymphoblastic Leukemia Relapse Is Driven By Chemotherapy-Induced TSLP from Bone Marrow Stromal Cells

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Lineage Switch As a Relapse Mechanism of Pre-B Acute Lymphoblastic Leukemia Following CD19 CAR

CD19 CAR T Cells Maintain Efficacy in the Allogeneic Environment but Mediate Acute Graft-Versus-Host-Disease Only in the Presence CD19+ Acute Lymphoblastic Leukemia

41BBL-Based Activation and Expansion of Autologous Natural Killer Cells Results in Enhanced Activity Against Leukemia Including ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only